Vardenafil Hydrochloride Patent Expiration
Vardenafil Hydrochloride is Used for treating erectile dysfunction. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Vardenafil Hydrochloride Patents
Given below is the list of patents protecting Vardenafil Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Staxyn | US8613950 | Pharmaceutical forms with improved pharmacokinetic properties | Dec 23, 2028 | Bayer Hlthcare |
| Levitra | US8273876 | Medicaments containing vardenafil hydrochloride trihydrate | Jul 23, 2027 | Bayer Hlthcare |
| Levitra | US8841446 | Medicaments containing vardenafil hydrochloride trihydrate |
Jul 03, 2023
(Expired) | Bayer Hlthcare |
| Levitra | US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct 31, 2018
(Expired) | Bayer Hlthcare |
| Levitra | US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct 31, 2018
(Expired) | Bayer Hlthcare |
| Staxyn | US6362178 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct 31, 2018
(Expired) | Bayer Hlthcare |
| Staxyn | US7696206 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
Oct 31, 2018
(Expired) | Bayer Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vardenafil Hydrochloride's patents.
Latest Legal Activities on Vardenafil Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Vardenafil Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jun, 2025 | US8613950(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jun, 2021 | US8613950(Litigated) |
| Mail O.P. Petition Decision | 16 Jan, 2015 | US8613950(Litigated) |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 13 Jan, 2015 | US8613950(Litigated) |
| O.P. Petition Decision | 12 Jan, 2015 | US8613950(Litigated) |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 12 Jan, 2015 | US8613950(Litigated) |
| Adjustment of PTA Calculation by PTO | 07 Jan, 2015 | US8613950(Litigated) |
| Petition Entered | 21 Feb, 2014 | US8613950(Litigated) |
| Recordation of Patent Grant Mailed Critical
| 24 Dec, 2013 | US8613950(Litigated) |
| Patent Issue Date Used in PTA Calculation Critical
| 24 Dec, 2013 | US8613950(Litigated) |
Vardenafil Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vardenafil Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension | Respira Therapeutics, Inc. | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |